SCHEMBL25166334

SCHEMBL25166334

Clc1ccc2c(c1Br)OCCO2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.38
HTT P42858 3/20 0.38
MAPT P10636 1/20 0.38
BLM P54132 1/20 0.38
MAOB P27338 4/20 0.37
EGFR P00533 1/20 0.36
ITGB2 P05107 1/20 0.36
ICAM1 P05362 1/20 0.36
ITGAL P20701 1/20 0.36
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
POLB P06746 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
MTNR1A P48039 2/20 0.33
CRHBP P24387 2/20 0.32
CRHR2 Q13324 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30329793 1.00 LMNA (0.38) LMNAHTTMAPTBLMMAOB
SCHEMBL30329773 0.83 AOC3 (0.42) MAOBMEN1NPC1RAB9AKMT2A
SCHEMBL25166001 0.83 AOC3 (0.42) MAOBMEN1NPC1RAB9AKMT2A
SCHEMBL19765002 0.77 LMNA (0.39) LMNAHTTMAPTBLMMAOB
SCHEMBL16703954 0.75 MAPT (0.37) LMNAHTTMAPTMAOBITGB2
SCHEMBL25166705 0.75 HTT (0.38) LMNAHTTMAPTBLMMAOB
SCHEMBL25166294 0.75 LMNA (0.38) LMNAHTTMAPTBLMMAOB
SCHEMBL22827024 0.75 MAPT (0.38) LMNAHTTMAPTBLMMAOB
SCHEMBL29619656 0.75 MAPT (0.38) LMNAHTTMAPTBLMMAOB
SCHEMBL26005665 0.75 ALOX5 (0.44) LMNAHTTMAPTBLMITGB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2024-11-07 US disclosed
WO-2023064586-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF EHMT1, EHMT2, SHMT1 LMNA 3664/4885HTT 673/4885MAPT 2171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.